{"id":"idp-108","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"IDP-108 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as canagliflozin and empagliflozin, which have been shown to improve glycemic control and reduce cardiovascular risk in patients with type 2 diabetes.","oneSentence":"IDP-108 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:31.149Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT01008033","phase":"PHASE3","title":"Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis","status":"COMPLETED","sponsor":"Dow Pharmaceutical Sciences","startDate":"2009-11","conditions":"Onychomycosis","enrollment":870},{"nctId":"NCT01007708","phase":"PHASE3","title":"The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis","status":"COMPLETED","sponsor":"Dow Pharmaceutical Sciences","startDate":"2009-11","conditions":"Onychomycosis","enrollment":780},{"nctId":"NCT00777868","phase":"PHASE2","title":"A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis","status":"COMPLETED","sponsor":"Dow Pharmaceutical Sciences","startDate":"2007-10","conditions":"Onychomycosis","enrollment":135}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IDP-108","genericName":"IDP-108","companyName":"Dow Pharmaceutical Sciences","companyId":"dow-pharmaceutical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IDP-108 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}